Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer
2014 San Antonio Breast Cancer SymposiumIan E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with estrogen receptor–positive, aromatase inhibitor–resistant advanced or metastatic breast cancer: Part I results.”
Related Videos
Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer
Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06,
Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen...
Clifford A. Hudis, MD, FACP, on the SOFT Trial
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08,
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05,
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “...
Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial
Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
